NovaBridge Biosciences (NBP) Notes Payables (2018 - 2023)

NovaBridge Biosciences (NBP) has reported Notes Payables for 4 consecutive years, with $4.2 million the latest figure, recorded in Q4 2023.

• Quarterly Notes Payables rose 56.17% year-over-year to $4.2 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $4.2 million (up 56.17% YoY) and the FY2023 annual result came in at $4.2 million, down 99.85% from the prior year.
• Notes Payables climbed to $4.2 million in Q4 2023 per NBP's latest filing, from $4.1 million in the prior quarter.
• Over the last five years, Notes Payables for NBP reached as high as $7.1 million in Q4 2019 and fell as low as $2.7 million in Q4 2022.
• A 3-year average of $4.5 million and a median of $4.1 million in 2023 frame the typical range for Notes Payables.
• Annual changes were most pronounced in 2019 — Notes Payables tumbled 38.69% — and 2023, when it soared 56.17%.
• Year by year, Notes Payables stood at $7.1 million in 2019, then sank by 62.43% to $2.7 million in 2022, then surged by 56.17% to $4.2 million in 2023.
• According to Business Quant data, Notes Payables over the past three periods registered $4.2 million, $4.1 million, and $2.7 million for Q4 2023, Q2 2023, and Q4 2022 respectively.